Certara (NASDAQ:CERT) Releases FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.310-0.340 for the period, compared to the consensus estimate of 0.310. The company issued revenue guidance of $427.2 million-$431.4 million, compared to the consensus revenue estimate of $380.9 million.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings downgraded Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. KeyCorp raised their price target on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, October 16th. UBS Group cut shares of Certara from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research report on Wednesday, September 30th. Barclays upped their price objective on shares of Certara from $7.50 to $9.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Finally, TD Cowen increased their price objective on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.18.

Certara Price Performance

NASDAQ CERT traded up $1.09 during midday trading on Thursday, hitting $12.18. The company had a trading volume of 3,731,632 shares, compared to its average volume of 3,405,489. The company has a market capitalization of $1.86 billion, a PE ratio of -27.07 and a beta of 1.30. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The firm has a 50-day moving average price of $9.18 and a 200-day moving average price of $7.32. Certara has a twelve month low of $4.45 and a twelve month high of $12.25.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm had revenue of $94.90 million for the quarter, compared to analyst estimates of $92.01 million. During the same period last year, the firm earned $0.14 EPS. The business’s quarterly revenue was down 9.3% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, analysts anticipate that Certara will post 0.21 earnings per share for the current fiscal year.

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.